ENTIS official response to the EMA recommendations concerning ondansetron use by pregnant women

On the 18th September 2019, ENTIS issued an official response to the European Medicines Agency (EMA) Pharmacovigilance Risk Assessement Committee (PRAC) concerning the recommendations which were made about ondansetron use by pregnant women, as detailed in the minutes of their meeting held from the 8th to 11th July. The official ENTIS response statement can be read here.